---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-22-000105"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:47:46.925200+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q2 revenue $72.9M (+32% YoY); net loss $9.5M, EPS -$0.13

## Summary
- Revenue $72.9M, +32% YoY; testing $59.7M (+18%), biopharma $10.0M (vs $1.6M).
- Test volume 24,904, +19% YoY; GAAP gross margin 59%, non-GAAP 66%.
- Net loss $9.5M (+5% YoY), EPS -$0.13; non-GAAP op expenses $49.0M.
- Cash and investments $164.0M at June 30; operating cash flow improved $29.4M YTD.
- AUA/ASRO guideline now favorable for Decipher Prostate; multiple clinical data presentations at ASCO, ENDO, ESMO.

## SEC filing metadata
- accession: 0001384101-22-000105
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/0001384101-22-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/vcyt-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-22-000105
- JSON: https://secwatch.observer/filing/0001384101-22-000105.json
- Plain text: https://secwatch.observer/filing/0001384101-22-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.